Krystal Biotech (NASDAQ:KRYS) Stock Price Target Lowered at Citigroup

Posted by Francis Steltz on Nov 3rd, 2026

Krystal Biotech (NASDAQ:KRYS – Get Free Report) had its price target reduced by research analysts at Citigroup from $416.00 to $412.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s target price points to a potential upside of 36.24% from the company’s current price.

A number of other brokerages also recently issued reports on KRYS. Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 23rd. HC Wainwright reissued a “buy” rating and set a $361.00 target price on shares of Krystal Biotech in a research report on Thursday, October 15th. Bank of America raised their target price on shares of Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Zacks Research lowered shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a report on Friday, October 23rd. Finally, Royal Bank Of Canada reduced their price target on Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating on the stock in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $375.00.

Read Our Latest Analysis on Krystal Biotech

Krystal Biotech Stock Performance

KRYS stock traded up $6.50 during midday trading on Tuesday, reaching $302.40. 245,783 shares of the company traded hands, compared to its average volume of 328,258. Krystal Biotech has a 52-week low of $192.52 and a 52-week high of $382.54. The business has a 50 day moving average of $336.45 and a 200-day moving average of $308.70. The firm has a market capitalization of $8.95 billion, a price-to-earnings ratio of 37.88 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.26. The business had revenue of $127.34 million for the quarter, compared to the consensus estimate of $125.77 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. Research analysts anticipate that Krystal Biotech will post 7.33 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Dino Rossi sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KRYS. BlackRock Inc. acquired a new position in Krystal Biotech in the 2nd quarter worth approximately $1,554,113,000. William Blair Investment Management LLC purchased a new stake in shares of Krystal Biotech in the 2nd quarter valued at $211,909,000. Jupiter Topco LLC acquired a new stake in shares of Krystal Biotech in the second quarter worth $95,387,000. Bank of America Corp DE purchased a new position in shares of Krystal Biotech during the second quarter worth $95,308,000. Finally, First Trust Advisors LP raised its holdings in shares of Krystal Biotech by 42.9% during the first quarter. First Trust Advisors LP now owns 350,521 shares of the company’s stock worth $90,547,000 after purchasing an additional 105,245 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech News Summary

Here are the key news stories impacting Krystal Biotech this week:

Positive Sentiment: Krystal reported third-quarter earnings of $2.05 per share, above consensus estimates ranging from $1.79 to $1.92, while revenue of $127.34 million also exceeded expectations. The results were supported by approximately 30% revenue growth. Krystal Biotech Q3 earnings beat
Positive Sentiment: The company authorized a $400 million share-repurchase program over two years. Buybacks can support near-term earnings per share and signal management’s confidence in the stock’s value. Krystal $400 million buyback
Positive Sentiment: TD Cowen and Royal Bank of Canada lowered their price targets to $380 and $375, respectively, but retained bullish ratings of Buy and Outperform. Both targets imply substantial upside from recent trading levels. TD Cowen rating Royal Bank of Canada rating
Neutral Sentiment: The earnings beat and buyback have improved the investment case, but commentary indicates KRYS remains above some measures of fair value. Investors may therefore require continued Vyjuvek growth and pipeline progress to justify the valuation. Krystal remains above fair value
Negative Sentiment: Third-quarter earnings declined from $2.66 per share a year earlier to $2.05, despite the consensus beat. That year-over-year deterioration likely contributed to the negative market reaction. Krystal Q3 profit decline
Negative Sentiment: Several pipeline milestones have shifted into 2027, raising concerns about execution and delaying potential catalysts. The company also revised 2026 non-GAAP operating-expense guidance to $155 million-$165 million, highlighting ongoing investment and funding risks. Krystal pipeline timeline update

Krystal Biotech Company Profile

(Get Free Report)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.